First Wave Biopharma Inc (FWBI)

$2.96

Live

Highlights

Market Capitalization
6.0M
Book Value
$7.99
Earnings Per Share (EPS)
-47.88
Wall Street Target Price
36.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-27.07%
Return On Equity TTM
-15.28%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-20.9M
Diluted Eps TTM
-47.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.8
EPS Estimate Next Year
-1.55
EPS Estimate Current Quarter
-2.43
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for First Wave Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1116.22%

Current $2.96
Target $36.00

Technicals Summary

Sell

Neutral

Buy

First Wave Biopharma Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Citadel Advisors Llc

    0.26%
  • Tower Research Capital LLC

    0.18%
  • UBS Group AG

    0.10%

Company Information

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Organization
First Wave Biopharma Inc
Employees
9
CEO
Mr. James R. Sapirstein M.B.A., R.Ph.
Industry
Miscellaneous

FAQs